Swedish life science demonstration laboratory
GE Healthcare has opened a key technology facility, the GE Healthcare Life Sciences Demonstration Laboratory, at the Science for Life Laboratory in Stockholm, Sweden.
GE Healthcare has opened a key technology facility, the GE Healthcare Life Sciences Demonstration Laboratory, at the Science for Life Laboratory (SciLifeLab) in Stockholm, Sweden. The laboratory, which is equipped with the company’s latest tools and technologies for life sciences research, plans joint research collaborations with SciLifeLab scientists as they seek to understand the latest challenges in human disease.
Mathias Uhlénd, director of SciLifeLab Stockholm, said, "Our vision for SciLifeLab is to create a world-leading centre for molecular biosciences and medical research to foster greater understanding of the nature of human diseases. GE’s Demonstration Laboratory will be a significant and positive addition to the SciLifeLab.”
"The SciLifeLab is assembling a world class multidisciplinary team to study some of medicine’s most pressing problems," said Peter Ehrenheim, retiring CEO of GE Healthcare Life Sciences. “We now know that many of the future advances in medicine will be driven by advances in our understanding of cellular mechanisms at the molecular level. GE Healthcare has a long history of innovation in life sciences, and we are committed to grow in partnership with our customers. The GE Healthcare Life Sciences Demonstration Laboratory will help us to do just that."
The laboratory is equipped with the company’s newest technologies for protein, cell biology and biomedical research. By helping the company gain a deeper understanding into the use of its technologies in a research environment, the laboratory also promises to help drive the future development of new innovations for life sciences research.
For more information about the company visit www.gehealthcare.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
